Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
about
Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanOATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesPediatric Statin Administration: Navigating a Frontier with Limited DataPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsOrganic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugsEffects of rifampicin, dexamethasone, St. John's Wort and Thyroxine on maternal and foetal expression of Abcb1 and organ distribution of talinolol in pregnant ratsTransport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3.Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transportXenobiotic, bile acid, and cholesterol transporters: function and regulation.Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia.The SLCO (former SLC21) superfamily of transporters.Novel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureThe impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Impact of OATP transporters on pharmacokinetics.Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport.Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.Risk factors for idiosyncratic drug-induced liver injury.The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets DeterminationInhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383Synthesis, in vitro and in vivo evaluation of 3β-[18F]fluorocholic acid for the detection of drug-induced cholestasis in miceRole of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytesEffect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administrationFrequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.
P2860
Q26851546-833FEC8F-95A0-48C6-8DB0-1AA9A24CF118Q27001267-3EF999F1-D5B0-4045-B46F-D9F5EA4BD34BQ28068014-FF58A9DF-A50A-45EA-ADDA-1EA5E6C5A62CQ28478275-76F6ECB8-D94F-46D3-AFC6-81C293B3E73BQ28506256-7C555695-7CEF-4B56-AF90-E59F88246854Q28568297-9F118DCC-9519-4752-A7DE-21B6CA01AF08Q33236324-DBE5815B-F142-475D-840B-68E81A3E64C9Q33423486-21280575-B217-421A-9250-74B8AF0E42D1Q33442288-B7D2BDDB-1C79-41F0-9A69-D0C1D290002BQ33714593-13BA87C9-2359-4D15-8282-294903610CEDQ33829256-DE6B43F3-F59F-467E-B0D3-00ADDDE69A5DQ34058706-2E213AFE-9498-443B-AF86-D2817B831126Q34094825-E54048D4-D730-4A1F-B0B2-94D8D2A504C3Q34242199-E40F442D-D882-487F-838A-6231F9AC3A95Q34317491-0389D2D5-F7DA-40B1-8BE7-1E78EEB87DDAQ34333710-9F327F7B-819F-4BA5-8E18-1CE44DC434D8Q34360004-A392096B-805B-4EE2-9D4E-EA6FB21E2AB2Q34444338-2AEB8044-F137-4900-9DE9-0759EC966C6DQ34548528-F123F3D9-93CC-4F32-8001-2E70358D16B3Q34571070-A0B591EF-7DAA-4314-B499-2E929F9EF066Q34612244-6E1D11E4-AA9A-4A77-886D-A70DAC32344FQ34616433-56AA134A-7C5A-4323-8C0C-3727F366C9A7Q34782375-5C3111E8-29D7-4C1F-AE5C-18B647D81C75Q34969837-B4E16D6A-BA75-45A0-BD88-8483BC52B9A0Q35026167-EEF27BFB-BBA8-45A4-95E9-FEBA597B0972Q35039217-7DFA4FA5-8B29-42B6-ACC7-EAC5EDE1BB2FQ35080119-989EE149-17DF-440D-830A-FD3B5331FA63Q35120613-0DE007B2-F246-4C81-A2D9-DAE5319DDC8EQ35168108-EC502DC1-B3EC-4DD6-8C6D-DDAF90F22AAFQ35807991-82A3630C-E66C-4402-B91C-6328B208E8CAQ35825922-E5D4ECBB-4FA4-4E43-BDB5-098C5CDECBD3Q35827353-1B8385C5-8DAA-414F-845C-C3C002D46CFEQ35996034-F35EF3DD-1A67-4A5C-8F1F-0B298E699B6BQ36111214-5A150745-F9BF-43DE-A258-C940D49F0F0EQ36234390-6AEADED6-4ACB-4C4B-933F-F92862F04D15Q36300966-D1A91E94-ECA9-4E8F-BAEC-4F225051DFE2Q36544966-58E5A473-1BEE-41C5-AE58-1CCE11725A4BQ36573335-2BEE0477-9DE8-4C26-84BB-767F677D910AQ36578014-D1EA54BE-5F60-4602-B6EC-D0CA1FF36D68Q36623470-8D3FDC89-9550-4E55-AC5C-D1506DA33287
P2860
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Interactions of rifamycin SV a ...... uptake systems of human liver.
@en
Interactions of rifamycin SV a ...... uptake systems of human liver.
@nl
type
label
Interactions of rifamycin SV a ...... uptake systems of human liver.
@en
Interactions of rifamycin SV a ...... uptake systems of human liver.
@nl
prefLabel
Interactions of rifamycin SV a ...... uptake systems of human liver.
@en
Interactions of rifamycin SV a ...... uptake systems of human liver.
@nl
P2093
P356
P1433
P1476
Interactions of rifamycin SV a ...... uptake systems of human liver.
@en
P2093
Huy Riem Ha
Jessica Van Montfoort
Karin Fattinger
Peter J Meier
Stephan R Vavricka
P304
P356
10.1053/JHEP.2002.34133
P407
P577
2002-07-01T00:00:00Z